Table 1 Selected baseline characteristics of the cases and controls, PLCO studya

From: Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial

 

Controls

Cases

P -value

N

380

380

 

Age at blood collection, years

64

64

Matched

Race, %

   

 White, non-Hispanic

90.8

90.8

 

 Black

4.5

4.5

 

 Other races

4.7

4.7

Matched

PSA at blood draw (ng ml−1)

1.4

2.1

<0.0001

Height, cm

178.4 (2.7)

178.0 (2.6)

0.371

Weight, kg

87.0 (14.3)

87.0 (13.7)

0.930

BMI, kg m−2

27.4 (4.0)

27.5 (4.1)

0.659

Tobacco smoking status, %

   

 Never smoker

37.9

43.2

 

 Former smoker

56.3

52.4

 

 Current smoker

5.8

4.5

0.29

Tobacco smoking duration,b years

25.1 (12.9)

23.9 (13.3)

0.272

Family history of prostate cancer, %

3.6

5.4

0.073

Diabetes, %

6.1

7.1

0.56

Physical activity at age 40 (h per week), %

   

 4+ h (vs <3 h)

29.7

38.4

0.017

  1. Abbreviations: PLCO=Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; PSA=prostate-specific antigen; BMI=body mass index.
  2. aValues are means and standard deviations unless otherwise indicated.
  3. bTobacco smoking duration among current or former smokers.